Of these, more than half, or 1.3 million, are people who inject drugs (PWID) -- HIV infections caused by injecting drugs.
The study revealed that HIV-infected people are on an average six times more likely than HIV-uninfected people to have HCV infection.
The study shows that not only are people with HIV at much higher risk of HCV infection, groups such as people who inject drugs have extremely high prevalence of HCV infection - over 80 percent.
HIV and HCV infections are major global public health problems, with overlapping modes of transmission and affected populations.
Globally, there are 37 million people infected with HIV and around 115 million people with chronic HCV infection.
Improvement in the surveillance of HCV and HIV is imperative to help define the epidemiology of coinfection and inform appropriate policies for testing, prevention, care and treatment to those in need.
The study shows the need to scale up prevention interventions, such as needle and syringe programmes and opioid substitution therapy, as well as access to HIV and HCV treatment, to reduce morbidity and new infections, the researchers suggested.
The study, published online in The Lancet Infectious Diseases, systematically reviewed 783 medical studies from worldwide sources to build the first global estimates on the prevalence of HIV/HCV co-infection (measured by HCV antibody) as a public health problem.
The study revealed that HIV-infected people are on an average six times more likely than HIV-uninfected people to have HCV infection.
The study shows that not only are people with HIV at much higher risk of HCV infection, groups such as people who inject drugs have extremely high prevalence of HCV infection - over 80 percent.
HIV and HCV infections are major global public health problems, with overlapping modes of transmission and affected populations.
Globally, there are 37 million people infected with HIV and around 115 million people with chronic HCV infection.
Improvement in the surveillance of HCV and HIV is imperative to help define the epidemiology of coinfection and inform appropriate policies for testing, prevention, care and treatment to those in need.
The study shows the need to scale up prevention interventions, such as needle and syringe programmes and opioid substitution therapy, as well as access to HIV and HCV treatment, to reduce morbidity and new infections, the researchers suggested.
The study, published online in The Lancet Infectious Diseases, systematically reviewed 783 medical studies from worldwide sources to build the first global estimates on the prevalence of HIV/HCV co-infection (measured by HCV antibody) as a public health problem.
0 comments:
Post a Comment